Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers.

Understanding interactions occurring at the interface between nanoparticles and biological components is an urgent challenge in nanomedicine due to their effect on the biological fate of nanoparticles. After the systemic injection of nanoparticles, a protein corona constructed by blood components surrounds the carrier's surface and modulates its pharmacokinetics and biodistribution. Biomimicry-based approaches in nanotechnology attempt to imitate what happens in nature in order to transfer specific natural functionalities to synthetic nanoparticles. Several biomimetic formulations have been developed, showing superior in vivo features as a result of their cell-like identity. We have recently designed biomimetic liposomes, called leukosomes, which recapitulate the ability of leukocytes to target inflamed endothelium and escape clearance by the immune system. To gain insight into the properties of leukosomes, we decided to investigate their protein corona in vivo. So far, most information about the protein corona has been obtained using in vitro experiments, which have been shown to minimally reproduce in vivo phenomena. Here we directly show a time-dependent quantitative and qualitative analysis of the protein corona adsorbed in vivo on leukosomes and control liposomes. We observed that leukosomes absorb fewer proteins than liposomes, and we identified a group of proteins specifically adsorbed on leukosomes. Moreover, we hypothesize that the presence of macrophage receptors on leukosomes' surface neutralizes their protein corona-meditated uptake by immune cells. This work unveils the protein corona of a biomimetic carrier and is one of the few studies on the corona performed in vivo.

[1]  Morteza Mahmoudi,et al.  Personalized protein corona on nanoparticles and its clinical implications. , 2017, Biomaterials science.

[2]  M. Sherman,et al.  Effects of the protein corona on liposome–liposome and liposome–cell interactions , 2016, International journal of nanomedicine.

[3]  Alaaldin M. Alkilany,et al.  Protein corona: Opportunities and challenges. , 2016, The international journal of biochemistry & cell biology.

[4]  N. Khashab,et al.  Dissociation coefficients of protein adsorption to nanoparticles as quantitative metrics for description of the protein corona: A comparison of experimental techniques and methodological relevance. , 2016, The international journal of biochemistry & cell biology.

[5]  A. De Vita,et al.  Biomimetic proteolipid vesicles for targeting inflamed tissues , 2016, Nature materials.

[6]  Sumaira Ashraf,et al.  In vivo degeneration and the fate of inorganic nanoparticles. , 2016, Chemical Society reviews.

[7]  Katharina Landfester,et al.  Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. , 2016, Nature nanotechnology.

[8]  M. Mahmoudi Protein corona: The golden gate to clinical applications of nanoparticles. , 2016, The international journal of biochemistry & cell biology.

[9]  Marilena Hadjidemetriou,et al.  Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. , 2016, Nanoscale.

[10]  K. Landfester,et al.  Protein source and choice of anticoagulant decisively affect nanoparticle protein corona and cellular uptake. , 2016, Nanoscale.

[11]  G. Caracciolo,et al.  The protein corona of circulating PEGylated liposomes. , 2016, Biochimica et biophysica acta.

[12]  A. De Vizcaya-Ruiz,et al.  Protein corona acts as a protective shield against Fe3O4-PEG inflammation and ROS-induced toxicity in human macrophages. , 2016, Toxicology letters.

[13]  G. Caracciolo,et al.  Stealth effect of biomolecular corona on nanoparticle uptake by immune cells. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[14]  Chunying Chen,et al.  Reducing the cytotoxicity of ZnO nanoparticles by a pre-formed protein corona in a supplemented cell culture medium , 2015 .

[15]  G. Caracciolo,et al.  The biomolecular corona of nanoparticles in circulating biological media. , 2015, Nanoscale.

[16]  Marilena Hadjidemetriou,et al.  In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. , 2015, ACS nano.

[17]  Raimo Hartmann,et al.  Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. , 2015, ACS nano.

[18]  M. Mahmoudi,et al.  Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. , 2015, Nanoscale.

[19]  Giulio Caracciolo,et al.  Surface chemistry and serum type both determine the nanoparticle-protein corona. , 2015, Journal of proteomics.

[20]  R. Muller,et al.  Formation of a biocompatible protein corona on magnetic nanoparticles , 2015, International Workshop on Magnetic Particle Imaging.

[21]  Young-Rok Kim,et al.  The fate of calcium carbonate nanoparticles administered by oral route: absorption and their interaction with biological matrices , 2015, International journal of nanomedicine.

[22]  A. Milani,et al.  Crucial role of the protein corona for the specific targeting of nanoparticles. , 2015, Nanomedicine.

[23]  E. Tasciotti,et al.  Proteomic Profiling of a Biomimetic Drug Delivery Platform. , 2014, Current drug targets.

[24]  G. Caracciolo,et al.  The liposome-protein corona in mice and humans and its implications for in vivo delivery. , 2014, Journal of materials chemistry. B.

[25]  P. Charoenphol,et al.  Plasma Protein Corona Modulates the Vascular Wall Interaction of Drug Carriers in a Material and Donor Specific Manner , 2014, PloS one.

[26]  J. Vallée,et al.  Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. , 2014, Nanoscale.

[27]  S. Orrù,et al.  Altered brain protein expression profiles are associated with molecular neurological dysfunction in the PKU mouse model , 2014, Journal of neurochemistry.

[28]  Thomas J. Anchordoquy,et al.  Questioning the use of PEGylation for drug delivery , 2013, Drug Delivery and Translational Research.

[29]  Raimo Hartmann,et al.  Temperature: the "ignored" factor at the NanoBio interface. , 2013, ACS nano.

[30]  Giulio Caracciolo,et al.  Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[31]  I. Dianzani,et al.  Differential proteomic analysis in human cells subjected to ribosomal stress , 2013, Proteomics.

[32]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[33]  Warren C. W. Chan,et al.  Understanding and Controlling the Interaction of Nanomaterials with Proteins in a Physiological Environment , 2012 .

[34]  S. Orrù,et al.  Protein cross‐talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity , 2012, Proteomics.

[35]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[36]  C. Casals,et al.  Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[37]  Stefan Tenzer,et al.  Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.

[38]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[39]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[40]  Darren J. Martin,et al.  Differential plasma protein binding to metal oxide nanoparticles , 2009, Nanotechnology.

[41]  Dan Golick,et al.  Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures , 2009, Proteomics.

[42]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[43]  J. Benoit,et al.  Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. , 2006, Journal of biomedical materials research. Part A.

[44]  D. Leckband,et al.  Protein-Induced Changes in Poly(ethylene glycol) Brushes: Molecular Weight and Temperature Dependence , 2001 .

[45]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[46]  I. Szleifer,et al.  Protein adsorption on surfaces with grafted polymers: a theoretical approach. , 1997, Biophysical journal.

[47]  T. Allen,et al.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.

[48]  K. Dawson,et al.  Biomolecular Coronas Provide the Biological Identity of Nanomaterials , 2017 .

[49]  M. Mahmoudi,et al.  Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. , 2016, Biomaterials.

[50]  Francesco Salvatore,et al.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. , 2016, Nanomedicine.

[51]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[52]  M D Blaufox,et al.  Blood volume in the rat. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.